Why AstraZeneca Still Looks Underrated Despite Strong EPS Momentum

AstraZeneca PLC is a high-quality compounder leveraging mid-single-digit revenue growth into robust EPS gains, driven by oncology and pipeline execution.

Recent EU approval of Trixeo Aerosphere for asthma expands AZN's addressable market, reinforcing its Respiratory & Immunology franchise with durable, long-cycle growth potential.

AZN's pipeline momentum—six positive Phase III readouts and 30 approvals—underpins its long-term growth narrative despite isolated late-stage failures.

With reaffirmed guidance for mid-to-high single-digit revenue and low double-digit EPS growth, AZN trades at a reasonable forward multiple, reflecting quality and pipeline durability.

I would be Buy-rated on AstraZeneca PLC ( AZN ) here, as this is a high-quality compounder in which mid-single-digit top-line growth is being leveraged into much stronger EPS growth via mix and pipeline execution, with oncology proving to